Haemonetics (HAE) Tops Q3 EPS by 3c; Sees FY17 Outlook at High End of Range
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $87.66 +1.67%
Revenue Growth %: +8.4%
Financial Fact:
Gross profit: 104.25M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +8.4%
Financial Fact:
Gross profit: 104.25M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q3 EPS of $0.43, $0.03 better than the analyst estimate of $0.40. Revenue for the quarter came in at $227.8 million versus the consensus estimate of $220 million.
Sees FY17 revenues and EPS at high end of range.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Customers Bancorp (CUBI) Tops Q1 EPS by 3c
- Arca Biopharma (ABIO) Reports Q1 Loss of $0.14
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
